2019 American Society of Clinical Oncology Annual Meeting*

Download All
May 31 - June 4, 2019; Chicago, Illinois
Review slidesets and analyses of key data from the 2019 Oncology meeting.

Gastrointestinal Cancers

Capsule Summary Slidesets

First-line FOLFOXIRI/bevacizumab followed by retreatment with the same regimen upon progression improved PFS2 compared with sequential FOLFOX/bevacizumab followed by FOLFIRI/bevacizumab in unresectable mCRC.

Released: June 2, 2019

In the phase III APACT trial, adding nab-paclitaxel to adjuvant gemcitabine did not significantly prolong DFS by independent review but improved OS in an interim analysis in resected pancreatic cancer.

Released: June 4, 2019

In KEYNOTE-240, pembrolizumab showed nonsignificant improvement in PFS and OS compared with placebo as second-line therapy in advanced HCC.

Released: June 4, 2019

Survival outcomes with trifluridine/tipiracil in patients aged ≥ 65 years or those with metastatic GEJ cancer were generally consistent with the overall patient population, and HRQoL outcomes were stable over time in the overall population.

Released: June 11, 2019

Avapritinib is active in patients with advanced GIST harboring PDGFRA Exon 18 mutations and in those who received ≥ 3 lines of prior therapies.

Released: June 5, 2019

Maintenance therapy with olaparib improved PFS vs placebo in patients with metastatic pancreatic cancer and germline BRCA mutations who had not progressed with platinum-based chemotherapy.

Released: June 6, 2019
Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Blueprint Medicines
Celgene Corporation
Taiho Oncology Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.